The biopharmaceutical developer confirmed Thursday that its drug conjugate is undergoing evaluation across four distinct patient populations. While the head and neck cancer group has officially transitioned to the next phase of the trial design, enrollment remains active and on schedule for the remaining cohorts, which include individuals battling endometrial cancer, melanoma, and soft tissue sarcoma.
In section Market Quotes
MacroGenics Advances Head and Neck Cancer Drug Trial
MacroGenics has cleared a critical hurdle in its clinical investigation of MGC026, moving patients with recurrent or metastatic squamous cell carcinoma of the head and neck into the second stage of a Phase 1 study after hitting a pre-specified response threshold in initial testing.
Comments (0)
No comments yet. Be the first!